PPARgamma Activation by Losartan in Hypertensive Patients: The Importance of Losartan-Metabolites
试验速览
- 阶段
- 不适用
- 发起方
- 试验地点
- 1
研究概览
简要总结
The purpose of this study is to determine whether losartan metabolites are effective in inducing PPARγ target genes in monocytes in losartan-treated patients.
详细描述
The losartan metabolite EXP3179 potently induces the activity of the peroxisome proliferator-activated receptor γ (PPAR-γ) as a partial agonist in vitro. PPAR-γ is a nuclear hormone receptor and functions as a regulator of lipid- and glucose metabolism. PPAR-γ ligands improve insulin sensitivity and glucose tolerance, and reduce cardiovascular morbidity and mortality in diabetic patients.
Angiotensin II receptor 1-blocking and PPAR-γ-activating properties of losartan metabolites in patients would markedly improve the pharmacological profile of losartan by combining anti-hypertensive and highly beneficial metabolic actions. We developed the following hypothesis:
- Hypertensive patients chronically treated with losartan exhibit sufficient plasma levels of EXP3179 to activate PPARγ.
- PPARγ target genes are induced in monocytes from losartan-treated patients.
研究设计
- 研究类型
- Observational
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 19 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age: 19-80
- •Sex: male or female
- •Prior diagnosis of treated hypertension
- •Treatment with losartan 100mg/daily during at least the past 2 months (n=20/ case);
- •or: no prior angiotensin receptor 1-blocker treatment during the last 2 months (n=10/ control).
排除标准
- •Non-steroidal anti-inflammatory drugs (exception: Acetyl salicylic acid) for the past 21 days (due to structural homologies to glitazones, and activating effects on PPARγ)
- •Therapy with glitazones for the past 21 days.
研究组 & 干预措施
A
Patients chronically treated with drug losartan
干预措施: losartan (Drug)